And, here is ZLD extract from James Dunn's story in the Switzer Report (22 June 2020)
1. Zelira Therapeutics (ZLD, 5.6 cents)
Market capitalisation: $54 million
FY19 revenue: nil
Net profit: –$3.6 million
Three-year return: –10.8% a year
Zelira has one foot on the conventional
pharmaceutical side and one foot on the
over-the-counter healthcare market. In the former, its
patented medicinal cannabis formulation, ZLT-101, is
coming off a successful clinical trial against chronic
insomnia, which means Zelira is poised to launch the
world’s first clinically validated medicinal marijuana
formulation for insomnia into global markets in 2020.
To put this in context, at present there are only two
registered cannabis medicines in the world, Epidiolex
for epilepsy and the nose spray Sativex, for multiple
sclerosis spasticity, both owned by UK company GW
Pharma.
The company is also conducting a Phase 1 clinical
trial in patients experiencing long-term chronic pain.
Cannabinoid-based medication can potentially
provide an alternative treatment to opioids for chronic
pain, but the epidemic of opioid addiction has
clinicians looking for a non-drug treatment. Zelira also
has a clinical trial programs focused on insomnia and
autism.
Zelira also has a pre-clinical research program
examining the effect of cannabinoids in breast, brain
and pancreatic cancer; as well as research examining
the potential for cannabinoids to treat
diabetes-associated cognitive decline.
Zelira has also launched a pharmaceutical-grade
medicinal cannabis product called HOPE, which was
developed to specifically address patient symptoms
associated with Autism Spectrum Disorder. It was
launched in the US in May 2019 and is also being
sold in Germany and the UK; it will be launched in
Australia and Asia-Pacific later this year. The
company’s other proprietary product, CAN-001, is
being developed for the treatment of
chemotherapy-induced nausea and vomiting (CINV),
which occurs in approximately 80% of the new 23.6
million cases of cancer annually worldwide. From its
platform Zelira also plans to introduce products in
age-related disorders, oral healthcare and
dermatology.
Zelira has only just started earning revenue; but
against that, it will shortly be one of the few
companies in the world with an actual cannabis
medicine, that has passed clinical trials, launched into
global markets for a major unmet need.
(20min delay)